Ani pharmaceuticals inc (ANIP)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Licensing revenue

-

-

-

-

-

-

-

-

100

115

-

Grant revenue

-

-

-

-

-

-

-

-

-

51

116

Royalty revenue

-

-

-

-

-

-

-

-

335

2,306

1,141

Net Revenues

206,547

201,576

176,842

128,622

76,322

55,970

30,082

20,371

435

2,474

1,258

Operating Expenses:
Cost of sales (excluding depreciation and amortization)

63,154

73,024

79,032

48,780

12,692

11,473

9,974

9,167

-

-

-

Research and development

19,806

15,388

9,070

2,906

2,874

2,678

1,712

1,158

44,182

39,705

13,680

Selling, general, and administrative

55,843

44,063

31,580

27,829

21,156

17,935

16,388

9,521

6,981

5,940

5,373

Acquired in-process research and development

-

-

-

-

-

-

-

-

-

-

9,000

Excess consideration paid over fair value

-

-

-

-

-

-

-

-

-

-

20,192

Licensing expense

-

-

-

-

-

-

-

-

50

268

299

Depreciation and amortization

44,612

33,742

27,928

22,343

6,900

3,878

1,110

567

148

167

137

Cortrophin pre-launch charges

6,706

0

0

-

-

-

-

-

-

-

-

Intangible asset impairment charge

75

0

903

6,685

0

0

-

-

-

-

-

Total Operating Expenses

190,196

166,217

148,513

108,543

43,622

35,964

29,184

20,413

51,361

46,082

48,683

Operating (Loss)/Income

16,351

35,359

28,329

20,079

32,700

20,006

898

-42

-

-

-

Other Expense, net
Interest expense, net

-12,966

-14,758

-12,035

-11,327

-11,008

-787

-467

1,327

681

688

147

Convertible note fair value adjustment

-

-

-

-

-

-

-

-

-23

-1,870

33

Investment impairment charge

-

-

-

-

-

-

-

-

-

286

-

Other income /(expense), net

-228

-550

55

-74

41

160

-305

-241

-

-

-

(Loss)/Income Before Benefit/(Provision) for Income Taxes

3,157

20,051

16,349

8,678

21,733

19,379

126

-1,610

-51,608

-46,196

-

Benefit/(provision) for income taxes

-2,937

4,557

17,425

4,744

6,358

-9,368

20

-36

-

-

-

Net Income from Continuing Operations

-

-

-

-

-

-

106

-1,574

-

-

-

Discontinued Operation
Gain on discontinued operation, net of $38 provision for income taxes in the year ended December 31, 2013

-

-

-

-

-

-

-195

-68

-

-

-

Net (Loss)/Income

6,094

15,494

-1,076

3,934

15,375

28,747

301

-1,506

-

-

-

Net Income from Continuing Operations

-

-

-

-

-

-

106

-1,574

-

-

-

Preferred stock dividends

-

-

-

-

-

-

4,975

6,922

-

-

-

Income/(Loss) from Continuing Operations Attributable to Common Stockholders and Participating Securities

-

-

-

-

-

-

-4,869

-8,496

-51,608

-46,196

-47,527

Other income

-

-

-

-

-

-

-

-

15

244

-

Interest income

-

-

-

-

-

-

-

-

8

12

11

Continuing operations (in dollars per share)

-

-

-

-

-

-

-0.96

-

-

-

-

Discontinued operation (in dollars per share)

-

-

-

-

-

-

0.04

-

-

-

-

Basic (Loss)/Earnings Per Share

0.51

1.31

-0.09

0.34

1.34

2.61

-0.92

-

-3.15

-4.21

-8.40

Continuing operations (in dollars per share)

-

-

-

-

-

-

-0.96

-

-

-

-

Discontinued operation (in dollars per share)

-

-

-

-

-

-

0.04

-

-

-

-

Diluted (Loss)/Earnings Per Share

0.50

1.30

-0.09

0.34

1.32

2.59

-0.92

-

-3.15

-4.21

-8.40

Weighted average number of common and common equivalent shares outstanding:
Basic Weighted-Average Shares Outstanding

11,841

11,677

11,547

11,445

11,370

10,941

5

-

16,397

10,985

5,658

Diluted Weighted-Average Shares Outstanding

12,040

11,772

11,547

11,573

11,557

11,053

5

-

16,397

10,985

5,658

Continuing operations (in dollars per share)

-

-

-

-

-

-

-

0.00

-

-

-

Discontinued operation (in dollars per share)

-

-

-

-

-

-

-

0.00

-

-

-

Basic and Diluted Income/(Loss) Per Share (in dollars per share)

-

-

-

-

-

-

-

0.00

-

-

-

Basic and Diluted Weighted-Average Shares Outstanding (in shares)

-

-

-

-

-

-

-

0

-

-

-